# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-01-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for new patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests. **S**

## Objective

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 28 mg/dL (high); Glucose (fasting): 94 mg/dL; Creatinine: 1.42 mg/dL (high); eGFR, creatinine (CKD-EPI 2021, race-free): 40 mL/min/1.73 m² (low); Cystatin C: 1.68 mg/L (high); eGFR, creatinine and cystatin C (CKD-EPI 2021, race-free): 38 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 240 mg/g (high); Hemoglobin A1c: 5.6%; Hemoglobin: 11.2 g/dL (low); Ferritin: 168 ng/mL; Transferrin saturation: 24%; Calcium: 9.2 mg/dL; Phosphate: 3.8 mg/dL; Parathyroid hormone, intact: 84 pg/mL (high); 25-hydroxyvitamin D: 17 ng/mL (low); Total cholesterol: 214 mg/dL (high); LDL cholesterol: 136 mg/dL (high); HDL cholesterol: 52 mg/dL; Triglycerides: 128 mg/dL; TSH: 1.9 mIU/L; PHQ-9: 4. All results are synthetic.

BP 164/94 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 70.4 kg; BMI 28.6 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established; Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**

## Plan

- Nephrology consultation for reduced kidney function (race-free eGFR 38) with albuminuria of uncertain cause, a 5-year kidney failure risk above 5% if the disease proves chronic, and APOL1 genetic counseling. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtain. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021) **S**
- Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weeks. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dye. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baseline. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
